Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate C4 Therapeutics Inc before investing.

In this article, we go over a few key elements for understanding C4 Therapeutics Inc’s stock price such as:

• C4 Therapeutics Inc’s current stock price and volume
• Why C4 Therapeutics Inc’s stock price changed recently
• Upgrades and downgrades for CCCC from analysts
• CCCC’s stock price momentum as measured by its relative strength

About C4 Therapeutics Inc (CCCC)

Before we jump into C4 Therapeutics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Want to learn more about C4 Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about C4 Therapeutics Inc.

C4 Therapeutics Inc’s Stock Price as of Market Close

As of August 09, 2024, 4:00 PM, CST, C4 Therapeutics Inc’s stock price was $5.40.

C4 Therapeutics Inc is down 6.74% from its previous closing price of $5.79.

During the last market session, C4 Therapeutics Inc’s stock traded between $5.67 and $5.93. Currently, there are 68.81 million shares of C4 Therapeutics Inc stock available for purchase.

Unfortunately, C4 Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

C4 Therapeutics Inc Stock Price History

C4 Therapeutics Inc’s (CCCC) price is currently down 19.4% so far this month.

During the month of August, C4 Therapeutics Inc’s stock price has reached a high of $7.36 and a low of $5.28.

Over the last year, C4 Therapeutics Inc has hit prices as high as $11.88 and as low as $1.06. Year to date, C4 Therapeutics Inc’s stock is down 8.47%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused C4 Therapeutics Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 08, 2024, there were 3 analysts who downgraded C4 Therapeutics Inc’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate C4 Therapeutics Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on C4 Therapeutics Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

C4 Therapeutics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about C4 Therapeutics Inc (CCCC) by visiting AAII Stock Evaluator.

Relative Price Strength of C4 Therapeutics Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 08, 2024, C4 Therapeutics Inc has a weighted four-quarter relative price strength of 20.26%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how C4 Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

C4 Therapeutics Inc Stock Price: Bottom Line

As of August 9, 2024, C4 Therapeutics Inc’s stock price is $5.40, which is down 6.74% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like C4 Therapeutics Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.